idea-007 · viability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the investor, and the operator who would have to sell an implant plus a consumable stream into cash-pay veterinary practice.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-007.md — the number is the claim's position in its ## Claims list, the tag is copied from it and never adjusted here. A [no claim] marker means nothing in the file speaks to the condition at all. No number appears here that is not in a claim, and there is no ask slide. See docs/deck-spec.md.
What changed since the 2026-08-24 build: the research lane supplied a demand base [claim 29: unconfirmed], [claim 30: unconfirmed], two irreconcilable prevalence figures [claim 38: unconfirmed], [claim 39: unconfirmed], and the SUB precedent's long-term complication record [claim 32: unconfirmed], [claim 33: unconfirmed]. The last of those bears on the calendar, which is this deck's load-bearing question. Rebuilt from the file, not patched.
Would have to be true: The owner would have to pay cash for an implant and then keep paying for consumables — for years, on a cat with a terminal-course disease.
Where it stands: There is no third-party payer code of any kind and the claim was deliberately not run, because there is nothing to query [claim 7: unconfirmed]. The willingness-to-pay half is unbacked [claim 21: unconfirmed]. What the week supplied is evidence that the base behaviour is already a paid, sustained regimen: 85% of 468 surveyed CKD-cat owners were giving subcutaneous fluids at home [claim 29: unconfirmed], which is a population already buying consumables and already committed to a daily-care routine.
What would settle it: Practice interviews on how ongoing consumables are dispensed and priced in feline chronic care; pet insurance penetration and coverage of implants, human-attached.
If it's false: Revenue is one implant per cat, in a population whose treatment horizon is measured in a small number of years, and the unit economics have to work on that single sale.
Would have to be true: Nothing — and as with every veterinary candidate here, the useful work is saying why that is not automatically good news.
Where it stands: No code, no payer, no coverage [claim 7: unconfirmed]. Price is set by willingness to pay rather than by a fee schedule, with no floor underneath it. Compare idea-001 in this portfolio, where a fee schedule did exist and set that floor at a figure the file calls small — the trade runs both ways.
What would settle it: Nothing to look up. The work is willingness-to-pay research.
If it's false: It is not false; it is the market's structure.
Would have to be true: Enough managed CKD cats, at a defensible implant-plus-consumable price, with a reachable share.
Where it stands: All three components remain Generator assumptions [claim 8: unconfirmed], [claim 9: unconfirmed], [claim 10: unconfirmed] — and the prevalence evidence that arrived makes the denominator harder to state, not easier. A US feline-only practice cohort reported chronic kidney disease prevalence of 50% among cats randomly selected across four age groups, and 68.8% among cats recruited for degenerative joint disease studies [claim 38: unconfirmed]. A UK primary-care cohort of 353,448 cats across 244 clinics reported 1.2% (95% CI 1.1%-1.3%) [claim 39: unconfirmed]. Those differ by more than an order of magnitude because they are answering different questions — a screened feline-specialty population versus recorded diagnoses in general practice — and a TAM built on either without saying which is a number without a meaning. The obtainable-share assumption is narrower still: cats whose owners are already doing home subcutaneous fluids [claim 10: unconfirmed], for which [claim 29: unconfirmed] now gives a rate within the managed population.
What would settle it: Practice-level data on how many cats are on home fluids and for how long — which is the denominator the obtainable-share claim actually needs, and which neither prevalence study supplies.
If it's false: TAM is a hard kill condition, and — as with every veterinary candidate here — it is the factor least likely ever to reach verified through this pipeline, since no connector sees this market at all.
Would have to be true: Material qualification, sterile packaging validation and a case series would have to be the whole bill — with no premarket submission in the way.
Where it stands: The estimate is unbenchmarked [claim 14: unconfirmed] and rests on the regulatory position, which is the file's one solid ground: veterinary-only manufacturers need not register or list [claim 2: verified], with the human counterfactual now precisely identified as Class II under 21 CFR 880.5965 [claim 36: verified]. The problem the last build named is unchanged and is now better evidenced: the capital claim prices a case series as a line item while the safety premise it must settle [claim 13: unconfirmed] requires multi-year follow-up. The SUB literature shows what that timescale looks like in practice — device-generation comparisons and long-term outcome studies across 80 to 95 devices [claim 32: unconfirmed], [claim 33: unconfirmed] are the shape of the evidence base this product would need to build.
What would settle it: A quote for implant material qualification and sterile packaging; a teaching-hospital case-series protocol costed at the follow-up duration the oncologic question actually requires, rather than at the duration the budget prefers.
If it's false: The cheap-and-fast premise fails on the calendar rather than on the money — years of follow-up before the central safety claim can be made.
Would have to be true: The low-fouling surface chemistry and the metered giving set would have to be genuinely defensible — because nothing else is.
Where it stands: The moat claim names those two assets [claim 11: unconfirmed], and the file states the structural problem: fast-follower risk is elevated precisely because there is no premarket review to delay a competitor [claim 12: unconfirmed]. Both moat halves are weaker than they look. The surface chemistry is the answer to a fouling problem the SUB record shows is real and hard [claim 32: unconfirmed] — which makes it valuable if it works and makes the incumbent, who has been iterating on this exact class of failure across device generations [claim 33: unconfirmed], the party best placed to solve it too. The giving set is defeatable by substituting a generic syringe into the same port unless the design prevents it [claim 22: unconfirmed]. FTO — the only structural protection — was never asked [claim 28: unconfirmed].
What would settle it: A patent landscape on implanted subcutaneous ports and metered delivery sets, where the SUB manufacturer is the obvious assignee to start from; and a practical test of whether the port design can even accept a generic needle.
If it's false: A commodity implant with a defeatable consumable, in a market with no regulatory barrier to entry.
Would have to be true: The incumbents — existing feline subcutaneous fluid ports and the SUB device manufacturer — would have to be beatable, and knowable.
Where it stands: Better known than at the last build, and the picture is of an active incumbent rather than a static one. The SUB manufacturer has shipped at least three device generations, with measurable improvement between them: catheter kinking from 15.5% to 0%, and 90-day survival from 75% to 94% [claim 33: unconfirmed]. That is a competitor with a clinical evidence base, a surgical relationship and a demonstrated iteration cadence in this exact species and anatomy [claim 15: unconfirmed], [claim 6: unconfirmed]. The competitive picture still cannot be scanned: openFDA holds no records for animal-only devices, so an empty clearances or recalls result here is coverage absence, never competitive absence. The one adjacent human code that is visible returns a structural null of its own [claim 37: unconfirmed].
What would settle it: Distributor catalogues (Covetrus, Patterson Vet, MWI); VMX/WVC exhibitor lists; ACVIM/ACVS abstract books. The patent connector is the one tool that sees this field honestly.
If it's false: Read it inverted — the risk is a field this pipeline is blind to, with an established implanted-port manufacturer already holding the surgical relationship and now demonstrably improving its product.
Would have to be true: A patent search and two catalogues would have to establish whether this is enterable, before any material qualification is paid for.
Where it stands: Unchanged, unspent, and now joined by something cheaper and more decisive. The patent landscape remains the only automatic-kill condition here and has never been attempted [claim 28: unconfirmed]. Ahead of it in value-per-hour is reading PMID 40011049 closely enough to establish whether SUB mineralization [claim 32: unconfirmed] is a urine-chemistry phenomenon that does not transfer to a crystalloid port, or a surface-and-dwell-time phenomenon that does — because that answer changes the material-qualification programme, the case-series design and the moat argument at once.
What would settle it: That reading, then the patent landscape, then the catalogues, then the owner research.
If it's false: Nothing here is false — this is a work order.
Every condition above with nothing verified behind it. Two verified claims exist [claim 2: verified], [claim 36: verified] and both concern regulatory classification.
Eleven new claims since the last build and not one moved a tag. No commercial claim in this file has ever been verified and on current tooling none can be — there is no CMS for animals.
If only one thing from this chair could be checked: how long the case series has to run before anything can be said about tumour incidence — and what that does to the capital claim [claim 14: unconfirmed], [claim 13: unconfirmed].
Every other viability question here is ordinary veterinary-market uncertainty. This one is different in kind: the product's central safety premise is unasserted by design [claim 13: unconfirmed], the evidence that would settle it is a multi-year prospective feline series, and the file prices first revenue as though that study were a line item rather than the gating path. An investor's real question is not the size of the round but its duration, and that duration is set by an oncologic follow-up nobody has costed.
The week's evidence adds a second, nearer clock that the capital plan also does not carry. Implanted feline ports mineralize in 19-50% of cases in the only long-term dataset available [claim 32: unconfirmed], and that failure arrives years before any tumour would. So the case series is not one study with one endpoint; it is a device-durability study whose answer lands first and could end the programme on its own, wrapped inside an oncologic study whose answer lands years later. The SUB manufacturer needed multiple device generations to work through problems of exactly this class [claim 33: unconfirmed]. Costing one series against one endpoint understates both the money and the calendar.
Naming it is not a recommendation, a gate, or a kill.